Rationale for treating primary Sjögren’s syndrome patients with an anti-CD6 monoclonal antibody (Itolizumab)

Autor: Alain Saraux, Jacques-Olivier Pers, Tinhinane Fali, Enrique Montero, Ruby Alonso, Valérie Devauchelle, Yves Renaudineau, Christelle Le Dantec
Přispěvatelé: LabEX IGO Immunothérapie Grand Ouest, Immunologie et Pathologie (EA2216), Université de Brest (UBO)-IFR148, Experimental Immunotherapy, La Habana, Cuba, Center for molecular Immunology, CHRU Brest - Service de Rhumatologie (CHU - BREST - Rhumato), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Laboratoire d'Immunologie et Immunothérapie
Rok vydání: 2013
Předmět:
Antigens
Differentiation
T-Lymphocyte
T-Lymphocytes
Itolizumab
MESH: Flow Cytometry
Cell Separation
Lymphocyte Activation
Protein Engineering
Salivary Glands
MESH: Protein Structure
Tertiary
0302 clinical medicine
Cell Movement
MESH: Cell Movement
MESH: Antigens
CD
Receptors
Scavenger
B-Lymphocytes
0303 health sciences
Flow Cytometry
3. Good health
MESH: Protein Engineering
Sjogren's Syndrome
Rheumatoid arthritis
[SDV.IMM]Life Sciences [q-bio]/Immunology
Clone (B-cell biology)
medicine.drug
MESH: Salivary Glands
medicine.drug_class
Immunology
Antibodies
Monoclonal
Humanized
Monoclonal antibody
MESH: Cell Separation
MESH: Cell Adhesion
03 medical and health sciences
MESH: Activated-Leukocyte Cell Adhesion Molecule
Antigens
CD
Cell surface receptor
MESH: B-Lymphocytes
Activated-Leukocyte Cell Adhesion Molecule
Cell Adhesion
medicine
Humans
MESH: Receptors
Scavenger
Scavenger receptor
MESH: Lymphocyte Activation
ALCAM
030304 developmental biology
030203 arthritis & rheumatology
MESH: Humans
business.industry
Multiple sclerosis
medicine.disease
Protein Structure
Tertiary
MESH: Sjogren's Syndrome
MESH: T-Lymphocytes
MESH: Antigens
Differentiation
T-Lymphocyte
MESH: Antibodies
Monoclonal
Humanized
business
Zdroj: Immunologic Research
Immunologic Research, Humana Press, 2013, 56 (2-3), pp.341-7. ⟨10.1007/s12026-013-8423-x⟩
ISSN: 1559-0755
0257-277X
DOI: 10.1007/s12026-013-8423-x
Popis: International audience; CD6 is a cell surface receptor expressed on the majority of T cells and a subset of B cells. When expressed, CD6 contributes to lymphocyte activation through its extracellular domain 1, while adhesion and cellular migration are related to the extracellular scavenger receptor cysteine-rich domain (SRCR-D)-3 of CD6. Itolizumab, clone T1h, is a newly developed humanized IgG1 monoclonal antibody that targets CD6 SRCR-D1 and blocks immune activation. Itolizumab has been proposed to be effective in autoimmune diseases such as rheumatoid arthritis, Sjögren's syndrome and multiple sclerosis. In Sjögren's syndrome, the utilization of itolizumab as therapeutic option is reinforced by our recent observation that ALCAM, the CD6 ligand, is overexpressed and that CD6-positive T and B cells are detected within salivary glands from Sjögren's syndrome patients. In this study, itolizumab-positive target cells were characterized within both peripheral blood and salivary glands in order to provide rational for anti-CD6 treatment in Sjögren's syndrome.
Databáze: OpenAIRE
Externí odkaz: